Table 1.
Biological and clinical characteristics of the three patients, by comparison with the RE‐VERSE AD trial group A (serious bleeding)
| RE‐VERSE AD group A n = 51 | Case 1 | Case 2 | Case 3 | |
|---|---|---|---|---|
| Age (year), Median (Range) | 77 (48–93) | 77 | 96 | 80 |
| Sex (%) | 63% male | F | F | M |
| Weight (Kg), Median (Range) | 70.5 (42.4–127.5) | 60 | 42 | 79.5 |
| Hemoglobin (g/L) | – | 39 | 98 | 137 |
| CHA2DS2‐VASc | – | 3 | 3 | 5 |
| Creatinine clearance (mL/min) | ||||
| Median (range) | 54 (16–187) | 66.6 | 16 | 64 |
| Dose of dabigatran (%) | ||||
| 150 bid | 27 | |||
| 110 bid | 67 | X | X | X |
| 75 bid | 2 | |||
| other | 4 | |||
| Indication for dabigatran (%) | ||||
| NVAF | 92 | X | X | X |
| VTE | 2 | |||
| Other | 6 | |||
| Type of bleeding (%) | ||||
| Intracranial | 35 | X | ||
| Trauma related | 18 | |||
| Gastro‐intestinal | 39 | X | X | |
| Other | 22 | |||
| Unbound dabigatran at entrance | ||||
| Concentration (ng/mL) Median (Range) | 84.4 (3.30–641) | 330 | 455 | 108 |
| TTd (sec) | 44.9 (29.7–110) | – | 75.61 | 42.81 |
| TT (sec) | – | >150 | 354 | 149 |
| Dabigatran maximal rebounce | ||||
| Time post‐reversion (h) | – | 24 | 43 | 40 |
| Concentration (ng/mL) | – | 104 | 51.23 | <30 |
| TTd (sec) | – | – | 37.6 | 32.6 |
| TT (sec) | – | >150 | 94 | 27.5 |
TTd, for diluted thrombin time; TT, for thrombin time; NVAF: non valvular atrial fibrilation; VTE: venous thrombo‐embolism.